Evidence of impaired cisapride metabolism in neonates

British Journal of Clinical Pharmacology

Volumn 52, Issue 4, 2001, Pages 419-425

  Tréluyer, Jean Marc ^a   Rey, E ^a   Sonnier, M ^b   Pons, G ^a   Cresteil, T ^b  

^a Universite Paris Rene Descartes ^*  (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Cisapride; CYP3A4; CYP3A7; Drug metabolism; Neonates

Indexed keywords

CISAPRIDE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DRUG METABOLITE; PRASTERONE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOTOXICITY; CATALYSIS; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; ENZYME ACTIVITY; FETUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROXYLATION; INFANT; LIVER MICROSOME; MALE; MAMMAL CELL; NEWBORN; NEWBORN DISEASE; PERINATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; BIOTRANSFORMATION; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISAPRIDE; CYTOCHROME P-450 ENZYME SYSTEM; FETUS; GASTROINTESTINAL AGENTS; HUMANS; INFANT, NEWBORN; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES;

EID: 0034786492     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01470.x     Document Type: Article

References (34)

1. Double-blind placebo-controlled study of cisapride in patients with nonspecific esophageal motility disorder accompanied by delayed esophageal transit
2. Cisapride in the control of symptoms in infants with gastroesophageal reflux: A randomized, double-blind, placebo-controlled trial
3. Cisapride in pediatric gastroesophageal reflux
4. Cisapride improves gastric emptying in mechanically ventilated, critically ill patients. A randomized, double-blind trial
5. Cisapride reduces postoperative gastrocaecal transit time after cardiac surgery in children
6. Long QT syndrome during high-dose cisapride
7. Cisapride and fatal arrhythmia
8. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential?
9. Cisapride-induced torsades de pointes
10. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin
11. Torsade de pointes induced by cisapride/clarithromycin interaction
12. Cisapride. Drug interactions of clinical significance
13. Prolongation of the QT interval related to cisapride-diltiazem interaction
14. Effects of cisapride on QTc interval in neonates
15. Cisapride: A survey of the frequency of use and adverse events in premature newborns
16. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers
17. Influence of grapefruit juice on cisapride pharmacokinetics
18. Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: In vitro studies of potential co-medication interactions
19. Gene structure of CYP3A4, an adult-specific form of cytochrome-P450 in human livers, and its transcriptional control
20. Fetus-specific CYP3A7 and adult-specific CYP3A4 expressed in Chinese hamster CHL cells have similar capacity to activate carcinogenic mycotoxins
21. Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver
22. Intralobular distribution and quantitation of cytochrome P-450 enzymes in human liver as a function of age
23. Expression of CYP3A in the human liver - Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth
24. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver
25. Delayed ontogenesis of CYP1A2 in the human liver
26. Ontogenesis of CYP2C-dependent arachidonic acid metabolism in the human liver: Relationship with sudden infant death syndrome
27. Expression of CYP2D6 in developing human liver
28. Synthesesteigerung und abbauhemung bei der vermchrung der mikrosomalen cytochrome P450 und b5 durch phenobarbital
29. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders
30. Long-term use of cisapride (Prepulsid) in premature neonates of less than 34 weeks gestational age
31. Long-term use of cisapride (Prepulsid) in premature neonates
32. Cisapride and proarrhythmia in childhood
33. Cisapride and proarrhythmia in childhood